Verona completes enrolment in pilot study of potential COVID-19 inhaler
Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4
Read More
Tag: Verona Pharma
Verona Pharma launches late-stage COPD trial programme
Phase III trial programme will evaluate nebulised ensifentrine in moderate-to-severe COPD
Read More
Verona begins pilot study of potential COVID-19 inhaler
Inhaled ensifentrine will be assessed in hospitalised patients
Read More
Verona announces positive results from Phase II COPD trial
Verona Pharma’s COPD inhaler has shown positive results in a Phase II study.
Read More
Verona’s RPL554 improves lung function in CF trial
London, UK-based Verona Pharma’s experimental phosphodiesterase therapy has hit targets in a mid-stage trial in patients with cystic fibrosis.
Read More
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).
Read More
Verona Pharma doses first patient in cystic fibrosis trial
Verona Pharma has enrolled and dosed the first patient in a clinical study assessing its investigational drug RPL554 as a treatment for cystic fibrosis (CF).
Read More
Verona signs up QuintilesIMS for respiratory drug development
London, UK-based clinical biopharma Verona Pharma has entered into a global strategic services agreement with biopharmaceutical development and commercial outsourcing services giant QuintilesIMS.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
